ALX Oncology reported $84 million in cash, cash equivalents, and investments as of June 30, 2025. By focusing resources on its most promising programs and pausing the ASPEN-CRC trial, the company has ...
ALX Oncology Holdings (NASDAQ:ALXO) presented its Q2 2025 results on August 12, 2025, highlighting its focused development strategy around evorpacept, a CD47-targeting immunotherapy, and ALX2004, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results